Core Viewpoint - Yibai Pharmaceutical (600594) announced that it expects a negative net profit for the fiscal year 2025, indicating an anticipated operational loss for the year [1] Financial Performance - The company’s financial department has conducted preliminary calculations, leading to the expectation of a loss in 2025 [1] - Yibai Pharmaceutical will adhere to the Shanghai Stock Exchange listing rules and expedite its financial accounting process [1] Future Disclosure - The company commits to disclosing the 2025 annual performance forecast within the stipulated timeframe [1] - The final financial data will be based on the officially disclosed audited annual report for 2025 [1]

Financial Performance Expectations - Guizhou Yibai Pharmaceutical Co., Ltd. expects a net profit attributable to shareholders to be negative for the fiscal year 2025, indicating an anticipated loss[1] - Final financial data will be based on the officially disclosed audited annual report for 2025[1] Compliance and Reporting - The company is accelerating its financial accounting processes to comply with the Shanghai Stock Exchange regulations and will disclose the 2025 performance forecast within the stipulated timeframe[1]

Core Insights - The article highlights that as of January 9, a total of 146 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is ST Renfu, which has seen net purchases for 12 consecutive trading days [1] - Other notable stocks with significant net buying days include *ST Yedao, Yibai Pharmaceutical, Fenglong Co., Ningbo United, Xingdesheng, Zhongchen Technology, Jinzong Co., and Funeng Co. [1] Summary by Category - **Market Activity** - A total of 146 stocks have recorded net buying from major funds for five days or more [1] - ST Renfu leads with 12 consecutive days of net buying [1] - **Notable Stocks** - Other stocks with considerable net buying include *ST Yedao, Yibai Pharmaceutical, Fenglong Co., Ningbo United, Xingdesheng, Zhongchen Technology, Jinzong Co., and Funeng Co. [1]

Core Viewpoint - As of January 7, a total of 137 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Huaneng Hydropower, which has seen net buying for 14 consecutive trading days [1] - Other notable stocks with significant net buying days include Meike Home, Aiko Photonics, ST Renfu, Yibai Pharmaceutical, Fenglong Co., ST Huapeng, Fuanna, and Yuanxin Industrial [1]

Core Insights - The 2025 Guizhou Top 100 Private Enterprises and Top 20 Private Manufacturing Enterprises were announced, showcasing the resilience and vitality of the private economy in Guizhou, which is becoming a significant force for high-quality development in the province [2][11]. Group 1: Rankings and Performance - The threshold for entering the 2025 Guizhou Top 100 Private Enterprises is set at 693 million yuan, an increase of 51 million yuan or 7.94% from the previous year [11]. - The total revenue of the top 100 enterprises reached 294.69 billion yuan, an increase of 7.96 billion yuan or 2.78% year-on-year [11]. - The manufacturing sector remains dominant, comprising over 60% of the top 100 enterprises, with 62 companies in this category [11]. Group 2: Characteristics of Top Enterprises - The top 100 enterprises exhibit five key characteristics: leading enterprises continue to excel, with three companies reporting revenues exceeding 10 billion yuan; the industrial structure is continuously optimized; R&D investment has significantly increased, with 2024 R&D expenses reaching 5.396 billion yuan, a year-on-year increase of 25.49% [11]. - There is a growing awareness of legal compliance and integrity, with 82 enterprises establishing legal risk control systems and 62 implementing bidding management systems [11]. - Social responsibility is actively pursued, with 51 enterprises participating in rural revitalization efforts, contributing to employment stability with an average of 1,738 jobs created per enterprise [11]. Group 3: Notable Companies - Zhongwei New Materials Co., Ltd. ranks first in the 2025 Guizhou Top 100 Private Enterprises, followed by Guizhou Tongyuan Group and Guizhou Geely Automobile Manufacturing Co., Ltd. [12][23]. - In the Top 20 Private Manufacturing Enterprises, Zhongwei New Materials Co., Ltd. also leads, followed by Guizhou Geely Automobile Manufacturing Co., Ltd. and Guiyang Hisense Electronics Co., Ltd. [23].

Group 1 - The Chinese medicine sector experienced a slight increase of 0.45% on December 18, with Yibai Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - Key stocks in the Chinese medicine sector showed varied performance, with Yibai Pharmaceutical closing at 4.29, up 5.67%, and other notable gainers including Jinhua Co. and Xinda Pharmaceutical [1] Group 2 - The Chinese medicine sector saw a net outflow of 362 million yuan from major funds, while retail investors contributed a net inflow of 384 million yuan [2] - Among the stocks, *ST Changyao experienced the largest decline, down 6.21% to 1.51, while Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also faced losses [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Zhongsheng Pharmaceutical recording a turnover of 910 million yuan despite a decline [2] Group 3 - Major funds showed a net inflow in stocks like Pianzi Shou and Lingrui Pharmaceutical, while retail investors had mixed results across different stocks [3] - The net inflow for Pianzi Shou was 22.60 million yuan, while other stocks like Guizhou Bailing and Taiji Group also saw notable fund movements [3] - The overall trend indicates a divergence in fund flows, with some stocks attracting significant retail interest despite overall sector outflows [3]

证券日报网讯 12月5日晚间，益佰制药发布公告称，中证天通会计师事务所（特殊普通合伙）（以下简 称"中证天通"）作为公司2025年度财务报表和内部控制的审计机构，原委派孙太宏担任公司2025年度财 务报表和内部控制审计报告的签字注册会计师，由于原第二签字注册会计师孙太宏已从中证天通离职， 现中证天通委派肖缨接替孙太宏作为公司第二签字注册会计师。变更后公司2025年度财务报表和内部控 制审计报告的签字注册会计师为李朝辉、肖缨，质量控制复核人为邵富霞。 （文章来源：证券日报） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600594 证券简称：益佰制药 公告编号：2025-040 贵州益佰制药股份有限公司 关于年度审计机构变更签字注册会计师的公告 肖缨不存在违反《中国注册会计师职业道德守则》对独立性要求的情形， 最近三年未受（收）到任何刑事处罚、行政处罚、行政监管措施和自律监管措 施,具备相应专业能力和丰富的从业经验。 三、本次变更对公司的影响 贵州益佰制药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开了第八届董事会第十一次会议，于 2025 年 5 月 16 日召开了 2024 年年度股东 大会，审议通过了《关于续聘公司 2025 年年度审计机构的议案》，同意续聘中 证天通会计师事务所（特殊普通合伙）（以下简称"中证天通"）为公司 2025 年年度财务报告及内部控制审计机构，具体内容详见公司于 2025 年 4 月 26 日 在上海证券交易所网站（www.sse.com.cn）披露的《贵州益佰制药股份有限公 司关于续聘公司 2025 年年度审计机构的公告》（ ...

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].

Group 1 - The National Healthcare Security Administration of China released a court criminal judgment excerpt regarding a bribery case involving Liu Mouhong, the director of the pharmacy department at Shuangshan Hospital in Anshan City [1] - Liu Mouhong utilized his position to assist others in drug procurement and increasing procurement volume [1] - The case is linked to Guizhou Yibai Pharmaceutical Co., Ltd., where a salesperson was involved in ensuring the supply of a specific product while excluding competitors [3] Group 2 - The judgment revealed that Liu Mouhong accepted a total of 6,000 yuan from a salesperson to facilitate the procurement of Yibai Pharmaceutical's Ginkgo Biloba injection [3] - The bribery occurred in September 2015 and January 2016, just before the Spring Festival [3] - The case highlights issues of corruption within the pharmaceutical procurement process in Chinese hospitals [3]